• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Genetika+ Raises $10M for Personalized Medicine for Psychiatry Solution

by Fred Pennic 09/30/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Genetika+ Raises $10M for Personalized Medicine for Psychiatry Solution
Genetika+ Co-Founders Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D

What You Should Know: 

– Genetika+, a female-founded startup focused on developing personalized medicine for psychiatry conditions, that the company has closed a $10 million Series A round led by GreyBird Ventures with participation from Meron Capital, Jumpspeed Ventures, Sapir Venture Partners, Howard Morgan Chairman of B Capital Group and Michael Zeisser of FMZ Ventures and former Chairman, Investments at Alibaba Group.

– Founded in 2018 by Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D., Genetika is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. The company’s Brain-in-a-Dish technology helps physicians find the best treatment for their patients.

Personalizing Depression Treatment

Genetika+  Raises $10M for Personalized Medicine for Psychiatry Solution

Depression affects daily functioning and quality of life for more than 300 million people worldwide, making it a leading cause of disability globally. Beyond the human cost, in the United States alone, the economic impact of the depression was more than $326 billion annually in 2018. During the COVID-19 pandemic, depression rates have risen threefold, with the largest increase in young adults. While a large number of antidepressants are available, there is currently no objective way for physicians to choose among these drugs based on a patient’s specific brain biology. Initially prescribed treatments are only successful about one-third of the time.

Genetika+’s lead solution personalized antidepressant treatment for each patient. The company’s novel Brain-in-a-Dish technology allows for a first-of-its-kind in vitro screen, in which a simple blood draw is used to predict the best antidepressant or combination therapy for that patient. This approach eliminates months or years of trial-and-error prescribing for depression patients, often accompanied by debilitating side effects. This solution for depression is just the beginning for Genetika+, which will apply its platform to develop personalized solutions for conditions across the psychiatric and neurological space.

Expansion Plans

The funding will accelerate the company’s next phase, including expanded clinical trials, increased manufacturing capabilities, and the establishment of a clinical lab in Boston, Massachusetts. The company is accelerating growth through increased hiring for multiple positions over the next 12 months in Boston and Israel to support research and business development activities across the U.S. market.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Behavioral Health, Personalized Medicine

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |